• It is unclear if protection by school age BCG vaccination against TB continues in adulthood when most transmission occurs
Background
Evidence of protection from childhood BCG against tuberculosis (TB) in adulthood, when most transmission occurs, is important for TB control and resource allocation.
Methods
We conducted a population-based case-control study of protection by BCG given to children aged 12 to 13 years against tuberculosis occurring 10 to 29 years later. We recruited UKborn white subjects with tuberculosis and randomly sampled white community controls.
Hazard ratios and 95% confidence intervals were estimated using case-cohort Cox regression, adjusting for potential confounding factors, including socio-economic status, smoking, drug use, prison and homelessness. Vaccine effectiveness (VE=1-hazard ratio)
was assessed at successive intervals more than 10 years following vaccination
Results
We obtained 677 cases and 1170 controls after a 65% response rate in both groups.
Confounding by deprivation, education and lifestyle factors was slight 10-20 years after vaccination, more evident after 20 years. VE 10 -15 years after vaccination was 51% (95% CI 21, 69%) and 57% (CI 33, 72%) at 15-20 years. Subsequently BCG protection appeared to wane; 20-25 years VE=25% (CI -14%, 51%) and 25-29 years VE= 1% (CI -84%, 47%).
Based on multiple imputation of missing data (in 17% subjects) VE estimated in the same intervals after vaccination were similar (56% (CI 33, 72%), 57% (CI 36, 71%), 25% (-10, 48%), 21% (-39, 55%).
Conclusions
School-age BCG vaccination offered moderate protection against tuberculosis for at least 20 years which is longer than previously thought. This has implications for assessing the costeffectiveness of BCG vaccination and when evaluating new TB vaccines.
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Background
Tuberculosis (TB) is a major, and potentially preventable, cause of morbidity and mortality globally with two to three billion of the world's population infected with Mycobacterium tuberculosis, 1 10% of whom progress to clinical disease. 2 In 2015, 10.4 million people were estimated to have developed TB. 1 TB incidence increases sharply in young adults 3 and most cases of pulmonary disease, the main source of onward transmission, occur in adults.
Progress in developing new TB vaccines is slow and BCG is the only licensed TB vaccine. 4 .
The efficacy of BCG in preventing TB varies geographically, particularly for pulmonary TB, with limited evidence of protection in many tropical areas. 5, 6 Recent evidence suggest that BCG may act in part by protecting against infection. 7 A large UK trial in the 1950s showed good protection against TB for upto 15 years following BCG vaccination of secondary school-children, 8 confirmed in observational studies to last at least 10 years after introduction into the UK national programme. 9 Although there are few data on protection, more than 10 years after vaccination, 10, 11 studies in Brazil, 12 in US Native-American populations 13 and, more recently, in the Norwegian general population 14 suggest BCG protection against TB can last longer. We aimed to provide confirmatory evidence of its durability in a case-control study of school-age BCG vaccination more than 10 years after vaccination in England. From the 1950s, BCG (based on the Danish strain 15, 16 ) was offered routinely to schoolchildren in the UK aged about 13 years, until the programme was discontinued in 2005.
Methods
From 2102 to 2014 cases and controls were invited to take part in face-to-face interviews and to be examined for a BCG scar. We assessed protection from BCG vaccination administered to children 10 to 30 years previously, in five-year intervals after vaccination and tested for trends over time by analysing time since vaccination on a continuous scale. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Experienced field interviewers carried out Computer-assisted Personal Interviews (CAPI),
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following training specific to the study including inspecting both arms of all subjects to identify BCG vaccination scars. The training included scar reading of volunteers with and without scars and examination of photographs. Formal supervisory field visits and blind telephone recall interviews of at least 10% of study participants (selected at random) were conducted for quality control.
No central databases of school vaccination records exist in the UK and records were not kept consistently in local child-health information systems. The classification of BCG vaccination status was based on a combination of participants self-reported history of BCG status (convincing history, probable history, no history) and scar inspection (present, not present, not examined). As BCG was a vaccine given in school at about 12-13 years and usually caused a pustule and then a scar, recall by cases and controls was considered likely to be good. However several had difficulties recalling whether or not they had had a tuberculin skin test (TST) (children were only eligible for BCG vaccination if they were considered TST negative). These subjects were not excluded from the analysis. Instead, we 
Ethics and consent
The study was approved by the UK's NHS National Research Ethics Service Committee. We obtained signed informed consent from those willing to take part. Participants, irrespective of whether they completed the study or not, were given a £15 gift voucher as compensation for their time. Hazard ratios (HR) for the association between BCG vaccination status and TB incidence were estimated using the case-cohort approach, with controls forming the sub-cohort.
19, 20
Controls were considered representative samples from the underlying population, as they were sampled at random from the underlying population within which cases arose (frequency matched by birth cohort in 5 year bands). TB rates are very low in the underlying population. The above approach allowed efficient use of data on the controls at different ages over time, as well as flexible modelling of vaccine effectiveness by time since vaccination. 21 Vaccine effectiveness (VE) was defined as VE=1-HR.
Based on a Cox regression model allowing a time-varying association between vaccination status and case-control status, each case was compared at its event time with all controls in the sub-cohort who were still at risk at that time (i.e. were interviewed at an age older than that of the case) and in the same year of birth stratum as the case. The time scale in these analyses was age, and vaccination status was a time-dependent variable. Self-reported age at vaccination, if available, was used to define vaccination status at a given age, otherwise the median age of 12 years in those reporting age at vaccination was assumed. The event time for cases was age at TB diagnosis, and the time of right censoring in controls was the age at interview for the study. Event times among cases were left-truncated on the day before the TB diagnosis date. Model parameters were estimated using a pseudo-partial likelihood analysis with robust standard errors as is required in a case-cohort analysis in which control groups are shared between cases 19, 20 . . were then added again one by one to the model and assessed for retention as before.
Analyses were conducted first for those who had complete data on the variables included in the final model. In sensitivity analyses we fitted the baseline and partially adjusted models on all individuals with complete data for the model in question. Analyses were repeated using multiple imputation by chained equations to deal with missing data, under a 'missing at random' (MAR) assumption. 23 (see details in Supplementary Methods available as supplementary data at IJE online).
Results
Of 1602 potentially eligible cases, 1047 (65%) were contacted successfully. Of these, 60
were ineligible (not born in the UK or not white) and 53 had difficulties precluding participation such as frailty. Of the remaining 934, 257 (28%) refused and 677 (72%) were 17 Of those enrolled 534 (80%) had pulmonary disease, 85% bacteriologically confirmed, the rest had extra-pulmonary disease of which 53% were laboratory confirmed.
We recruited controls by sampling 9424 residential addresses. For 13% the address no longer existed or no-one was at the address after repeated visits on different days and times.
Among 8176 screened addresses 1790 (22%) had at least one eligible resident. We recruited from these addresses 1170 controls, a 65% response rate 17 .
The distribution of visits by time of day and by day of week was similar in cases and controls 17 . The proportions of contactable cases was slightly lower for those living in more deprived areas based on IMD quintiles. The proportion of addresses successfully screened to identify eligible controls was similar across IMD quintiles. (see Supplementary Table 1, available as supplementary data at IJE online). Among eligible cases contacted, the refusal rate was slightly higher for those living in the least deprived quintiles. The proportion of addresses successfully screened to identify eligible controls was similar across IMD quintiles. Among subjects identified as eligible to be controls, the refusal rate was similar across IMD quintiles, though slightly higher than in cases. (see Supplementary figure 1, available as supplementary data at IJE online)
Cases were, more likely to be male, more likely to be in the most deprived IMD quintile, more likely to live in overcrowded households and had fewer educational qualifications than controls (Table 1) . Cases were more likely to report regular travel to or a long-term stay (≥3 months) in a high TB region. A higher proportion of cases than controls reported drinking at a hazardous or harmful level and reported being a smoker. The proportion of cases reporting having used class A drugs was twice as high as in controls. Similarly, a history of having ever been in prison or homeless was more frequent in cases than controls. 17 , information on self-reported history and scar examination were combined to classify the BCG status of participants, (as shown in Table 2 ). Controls were more likely to have had BCG vaccination than cases.
Estimated effects of BCG vaccine on TB according to time since vaccination, for each model, are shown in Table 3 . Area-level deprivation and education level met our retention criterion and were included in the partially adjusted model. In the fully adjusted model, we The results based on multiple imputation of the missing data also indicated lower protection more than 20 years after BCG vaccination (Table 3) . Estimated VEs were 56%, 57%, 25%
and 21%, 10-15, 15-20, 20-25 and 25-29 years since vaccination.
The association between BCG vaccination and log hazard of TB modelled using restricted 
Discussion
Based on a large, population-based case-control study there was about a 50% protection against TB between 10 and 20 years following school-age BCG vaccination, with little evidence of good protection after 20 years. Although numbers were small there appeared to be subsequent waning in protection. Results from complete-case analyses and multiple imputation to deal with missing data were consistent.
We had a moderately good response rate from cases and controls recruited to represent the children born in the UK in the general population. As we were able to locate few vaccination records we relied upon self-report of BCG vaccination and inspection of participants for BCG we were able to control for this in the analysis.
A limitation in our approach was the inability to assess and exclude subjects who had a positive tuberculin skin test (TST) in the school vaccination programme, who would have been ineligible for vaccination. Retrospective ascertainment of results of TST testing based on recall was not feasible, and participants' recall could not be validated in the absence of records. Persons who have a positive response to a TST are known to be at higher risk of TB during the first few years after testing. However follow-up data from the British MRC BCG trial in adolescents showed that, in that low transmission setting, the risk of TB in participants with a positive TST test declined over time, and was similar to that of subjects who were TST negative at baseline by about 10 years after enrolment 24, 25 (see figure 11 in ref 17 for details ).
Thus, not taking account of the TST results is unlikely to bias the association between BCG vaccination and TB beyond 10 years after vaccination. Also extrapolation from modelling work, 26 suggests that, in our study, the prevalence of tuberculin positivity in the white population would have been no greater than 4% at the time and age of screening for vaccination.
Other limitations include the possibility that subjects taking part are more likely to have been vaccinated than those not contactable or who had refused. Cases were somewhat harder to contact than controls. Together with a higher response rate in cases than in controls, this This study provides evidence that adds to that from the original UK MRC trial, in which protection of 63% was reported 10 to 15 years after vaccination (with wide 95% confidence intervals, 17 to 84%). In that trial there was no evidence of protection 15 to 20 years after vaccination but the numbers of cases were small and the confidence interval consequently very wide (VE 9%, 95% CI <0 to 71%). 24 The apparent waning of protection after 20 years has also been seen in Norway where moderately good protection was noted for 10-19 years after childhood BCG (VE 58% (CI 27%,76%), and lower protection 20-29 years after vaccination (VE 38%, CI -32 to 71%). 14 . In a Brazilian cohort protection in 15-20 year olds after infant BCG vaccination was 39% (9-58%), but with no data in older individuals. 27 Other evidence for the duration of protection in high prevalence settings is limited. A protective effect was noted in a case-control study in Saudi Arabian 15-24 year olds after infant BCG vaccination (VE 67%, 95% CI 55-77%), but not in 25 to 34 year olds (VE 20%, CI -6 to 37%). 28 In contrast in an extended follow up of a BCG trial in US Native-Americans protection up to 60 years was reported. 13 However it is unclear if such a long follow up might have acted to select those at lower risk of TB. The above studies also do not indicate whether the protective effect of BCG in childhood is more durable, when it is assumed immune responses are better, than in infancy.
It has been suggested that in high transmission settings and areas closer to the equator, masking of the effect of BCG occurs by infection or sensitisation by environmental mycobacteria increasingly providing, over time, some protection in the unvaccinated. 5, 6, 29, 30 The studies so far on durability of BCG have limited information with which to assess the role of masking.
In summary, our case-control study suggests BCG vaccination in UK-born adolescents 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 We suggest also including a recommendation for childhood vaccination when infant vaccination has not been given. Our finding of longer duration of BCG protection may be helpful for countries assessing the cost-effectiveness of BCG in the prevention of tuberculosis. It also has implications for assessing new vaccines against tuberculosis,which should desirablyprovide protection which is greater than that from BCG and which might also be expected to provide lasting protection, although assessment of the latter would, in the short term, have to be based on immunological characteristics.
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